Reshaping the HIV treatment and prevention landscape
Vaccines and Specialty Medicines priorities in key markets: China
China sales expected to triple
by 2026* driven by Vaccines
Illustrative
2017
Vaccines
Specialty Medicines
General Medicines
2021
2026
*Expected sales in 2026 with a 2021 base
Momentum with
Shingrix and Cervarix
Quarterly volume Sales (k doses)
希瑞适
CERVARIX
双价人乳头瘤病毒吸附疫苗
911
Strong trajectory for
innovative launches
IQVIA MQT Volume Share in SITT
TRELEGY ELLIPTA
574
487
503
gsk
46%
34%
322
18%
256
257
14% 16%
17% 16%
17%
9%
11%
230
141
2% 4%
Q1'19
Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21
20Mar
20May 20Jul 20Sep 20Nov 21Jan
4
SHINGRIX
HERPES ZOSTER ACCELE
80
70
59
COVID UMV
50
52
46
New Patient enrolment
Benlysta
(belimumab).
1,376
1,450
954
32
25
660
410
17
Jun 20 Jul 20 Aug'20 Sep' 20 Oct'20 Nov'20 Dec' 20 Jan'21 Feb'21 Mar'21
Internal sales data ('k doses)
2,210
Q3-4'19
Q1'20
Q2'20
Q3'20
Q4'20
Q1'21
Internal field force intelligence
39View entire presentation